Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 20, 2024 at 04:04 pm EST
Share
Halozyme Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 230.04 million compared to USD 181.5 million a year ago. Net income was USD 85.39 million compared to USD 57.7 million a year ago. Basic earnings per share from continuing operations was USD 0.66 compared to USD 0.43 a year ago. Diluted earnings per share from continuing operations was USD 0.65 compared to USD 0.42 a year ago.
For the full year, revenue was USD 829.25 million compared to USD 660.12 million a year ago. Net income was USD 281.59 million compared to USD 202.13 million a year ago. Basic earnings per share from continuing operations was USD 2.13 compared to USD 1.48 a year ago. Diluted earnings per share from continuing operations was USD 2.1 compared to USD 1.44 a year ago.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
HALOZYME THERAPEUTICS, INC. 
